ArticleCommunications biology2025
GDF11 alleviates glucocorticoid-induced osteonecrosis of the femoral head by regulating angiogenesis via the PI3K-AKT-eNOS pathway.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in glucocorticoid regulation of bone and the bone marrow niche: Genetic and pharmacological approaches to understand and prevent bone loss.Current opinion in endocrine and metabolic research · 2026Article
- Bone marrow mesenchymal stem cell exosomes in osteonecrosis: pathological mechanisms and therapeutic strategies.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Glucocorticoid-induced osteonecrosis of the femoral head is a joint dysfunction disease. Impaired local angiogenesis and reduced perfusion are early pathological features of glucocorticoid-induced osteonecrosis of the femoral head, resulting from vascular endothelial cell damage and suppressed angiogenesis caused by prolonged glucocorticoid exposure. This study focuses on the role of angiogenesis in glucocorticoid-induced osteonecrosis of the femoral head, particularly the potential of GDF11 in promoting angiogenesis. Our findings indicate that GDF11 expression diminished in patients with osteonecrosis of the femoral head compared to those with femoral neck fractures. We establish a male Sprague-Dawley rat model of glucocorticoid-induced osteonecrosis of the femoral head and utilize human umbilical vein endothelial cells to explore the role of GDF11 on osteogenesis and angiogenesis. A series of in vivo and in vitro experiments are conducted, the result shows that GDF11 could reverse the damaged angiogenic and osteogenic ability caused by methylprednisolone. We perform RNA sequencing in human umbilical vein endothelial cells and reveal that GDF11 promotes the expression of angiogenic factors and migration of endothelial cells through activating the PI3K/AKT/eNOS pathway, thereby promoting angiogenesis. Our study clarifies the role and mechanism of GDF11 in regulating local angiogenesis in glucocorticoid-induced osteonecrosis of the femoral head.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.